
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is a biotechnology company with a positive outlook on the development of their proprietary psychedelic treatment. With strong Phase II and III trial results and a growing acceptance in the medical community, the company has a valuable intellectual property position. However, there are still risks and uncertainties surrounding regulatory hurdles and potential disruptions to clinical trials. Nonetheless, the company is expected to file an NDA and has potential for partnerships outside of the US.
Bears say
Compass Pathways is heavily dependent on the success of their experimental drug, COMP360, for treatment-resistant depression (TRD). While they anticipate favorable payer responses and have a strong data package, there are still significant risks associated with successfully navigating the FDA approval process and building a commercial infrastructure. Additionally, the company is facing significant competition and financing challenges, which could impact their potential for success in the market. Overall, there is a lack of certainty and potential obstacles that make the future success of this company uncertain and risky, leading to the negative outlook on its stock.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares